Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | TMPRSS11D | O60235 | 12/20 | 0.43 |
| ▸ | F2 | P00734 | 6/20 | 0.43 |
| ▸ | F10 | P00742 | 6/20 | 0.43 |
| ▸ | PLG | P00747 | 3/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129383 | 0.92 | TMPRSS11D (0.42) | XIAPTMPRSS11DF2F10PLG | |
| SCHEMBL6094266 | 0.92 | TMPRSS11D (0.42) | XIAPTMPRSS11DF2F10PLG | |
| SCHEMBL6093256 | 0.89 | XIAP (0.46) | XIAP | |
| SCHEMBL6094023 | 0.88 | F2 (0.52) | TMPRSS11DF2F10PLGPRSS1 | |
| SCHEMBL6219378 | 0.88 | F2 (0.52) | TMPRSS11DF2F10PLGPRSS1 | |
| SCHEMBL6179226 | 0.87 | DPP4 (0.46) | — | |
| Hydrochloric Acid SCHEMBL6095357 | 0.86 | DPP4 (0.46) | — | |
| Hydrochloric Acid SCHEMBL7129856 | 0.86 | DPP4 (0.46) | — | |
| SCHEMBL6093799 | 0.85 | SCN4A (0.54) | TMPRSS11DF2F10PLG | |
| SCHEMBL6095928 | 0.85 | XIAP (0.46) | XIAPTMPRSS11DF2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | claimed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | claimed |
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | XIAP 2117/4885TMPRSS11D 112/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.